# Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating the Diagnostics Landscape with a 63.79% Potential Upside

- Link: https://www.directorstalkinterviews.com/myriad-genetics-inc-mygn-stock-analysis-navigating-the-diagnostics-landscape-with-a-63-79-potential-upside/4121245666
- Published: 2026-03-20T11:32:46+00:00
- Author: Madison Wilson

Investors focusing on the healthcare sector would do well to keep an eye on Myriad
Genetics, Inc. (NASDAQ: MYGN), a key player in the diagnostics and research industry.
With a market capitalization of $444.16 million, Myriad Genetics is a molecular 
diagnostics and precision medicine company based in Salt Lake City, Utah. The company
is renowned for its innovative molecular tests, which span oncology, women’s health,
and pharmacogenomics.

Myriad Genetics exhibits a current stock price of $4.75, fluctuating slightly with
a 0.11 (0.02%) increase. Over the past year, the stock has seen a 52-week range 
from $3.84 to $10.01, indicating substantial volatility that could interest risk-
tolerant investors. Despite its challenges, the company’s forward P/E ratio of 28.01
suggests that growth expectations remain embedded in its valuation.

One of the compelling aspects of Myriad Genetics is the significant potential upside
of 63.79%, based on the average target price of $7.78. Analysts have provided a 
broad target price range, from a conservative $4.00 to a more optimistic $18.00,
reflecting varied expectations about the company’s capacity to navigate current 
market conditions and capitalize on its product offerings.

However, investors should be cautious of the company’s fiscal metrics. Myriad Genetics
faces revenue growth challenges, having reported a -0.40% decline. Additionally,
the company currently operates with a negative EPS of -3.95 and a Return on Equity
of -68.45%, signaling underlying profitability issues. Despite these hurdles, the
company maintains a positive free cash flow of $762,500.00, demonstrating some financial
resilience.

Technical indicators present a mixed picture. The relative strength index (RSI) 
stands at a low 26.60, generally considered an oversold territory, potentially flagging
a buying opportunity for contrarian investors. Meanwhile, the stock trades below
both its 50-day and 200-day moving averages, suggesting a bearish sentiment in the
short to medium term.

Analyst ratings for Myriad Genetics include 3 buy ratings, 7 hold ratings, and 2
sell ratings. This distribution reflects a cautious optimism among analysts, with
many waiting for clearer signals of recovery or strategic pivots that could drive
meaningful stock appreciation.

The company’s product portfolio is robust and diverse, featuring critical tests 
such as the MyRisk Hereditary Cancer test and the BRACAnalysis CDx Germline Companion
Diagnostic test, among others. These offerings, combined with strategic collaborations
with notable institutions like Illumina, Inc. and the University of Texas M.D. Anderson
Cancer Center, position Myriad Genetics to potentially leverage its innovative capacity
into future growth.

For investors, the key consideration will be whether Myriad Genetics can effectively
address its performance challenges and capitalize on its technological and collaborative
strengths. The healthcare diagnostics space is rapidly evolving, and Myriad Genetics’
ability to innovate and adapt will be crucial to achieving the analyst-projected
potential upside.

As always, due diligence and a careful assessment of the risk-reward profile are
essential for investors considering a position in Myriad Genetics. With the healthcare
sector’s underlying growth and innovation prospects, Myriad Genetics remains a stock
worth watching.

Share on: